Business

Horizon Pharma has agreed to sell Raptor Pharmaceuticals, which owns the rights to Quinsair levofloxacin inhalation solution in Europe, the Middle East and Africa, to Chiesi Farmaceutici for $70 million and potential sales-based milestone payments,… Read more . . .

Windtree Therapeutics has received $900,000 from a Small Business Innovation Research Grant (SBIR) grant for Phase 2b trial of Aerosurf aerosolized KL4 surfactant in premature infants with respiratory distress syndrome (RDS) who are receiving nasal… Read more . . .

Pharmaxis has announced that Chiesi Farmaceutici will take over marketing and distribution of Bronchitol mannitol DPI in Italy. Bronchitol has been approved in the EU for the treatment of cystic fibrosis in patients 18 years… Read more . . .

Pulmatrix has announced the receipt of US patent No. 9,642,798, titled “Monovalent metal cation dry powders for inhalation,” which covers its PUR0200 dry powder formulation of tiotropium bromide for the treatment of COPD. In July… Read more . . .

According to intranasal drug developer OptiNose, the company has raised $37 million in a Series D financing round led by Fidelity Management and Research Company. The company said that it plans to use the money… Read more . . .

Innovus Pharmaceuticals will launch a fluticasone propionate nasal spray under the brand name FlutiCare in the US by the end of 2017 after acquiring rights to the product from West-Ward Pharmaceuticals International Limited (WWPIL). The… Read more . . .

The US Patent and Trademark Office has issued US Patent No. 9,572,774, titled “Dry Powder Vancomycin Compositions and Associated Methods,” to inhaled drug developer Savara, Inc., the company said. In its statement, the company added,… Read more . . .

AstraZeneca will pay $45 million up front and up to $2.1 billion in milestone and commercial payments to Pieris Pharmaceuticals for development and commercialization rights to Pieris’s inhaled anticalin therapies, Pieris said. In the near… Read more . . .

The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOAs) related to nasal delivery of CNS therapeutics. The projects described in FOAs RFA-DA-18-006 and RFA-DA-18-007 are both supported by Small Business… Read more . . .